__25J148Qli3.jpg)
我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息
16
Oct 2025
Latest News
ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation
ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.
Read More
19
Aug 2025
Performance
ScinoPharm Taiwan Continues Strategic Expansion in Formulation and CDMO Businesses
ScinoPharm Taiwan (Stock Code: 1789) held an online investor conference today to report its financial results for the first half of 2025. The company recorded consolidated revenue of US$45.2 million, equivalent to NT$1.434 billion, and a net profit after tax of NT$80 million.
Read More
15
Mar 2025
Performance
ScinoPharm Taiwan Maintains Stable Operations, Actively Expands into Formulation Development and CDMO Business
ScinoPharm Taiwan (Stock Code: 1789) held an investor conference today to report on its 2024 operational performance and business developments. The company achieved a consolidated annual revenue of NT$3.406 billion, marking a moderate 7% growth. Net profit after tax reached NT$339 million, reflecting an 18% year-over-year increase, with earnings per share (EPS) rising to NT$0.43.
Read More
19
Dec 2024
Latest News
ScinoPharm Partners with Handa Pharmaceuticals to Advance 505(b)(2) Drug Development
ScinoPharm Taiwan, Ltd. today announced a strategic investment in Handa Pharmaceuticals, Inc., marking the beginning of a collaboration to share R&D resources and leverage complementary strengths in advancing 505(b)(2) new drug development. This partnership will drive efforts in research, clinical trials, regulatory approvals, and product commercialization.
Read More
20
Nov 2024
Latest News
ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection, Expanding Its Presence in Emerging Markets
ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.
Read More